Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes

Aboelnaga, Engy M.; Aboelnaga, Mohamed M.; Elkalla, Hend M. Hamdey Rashed

doi:10.1016/j.dsx.2021.102251

Cited by 6 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 In addition, ADT can cause metabolic 45 and cardiovascular consequences, 46 and metformin is shown to ameliorate these adverse effects. 47 Metformin may also be used as an adjuvant to chemotherapy because it reduces the dose necessary to prolong remission. 48 As an adjuvant agent to radical radiotherapy, metformin may improve survival outcomes.…”

Section: Discussionmentioning

confidence: 99%

Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study

Lee¹,

Zhou

Hui

et al. 2022

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: The aim of this study was to compare the risks of new-onset prostate cancer between metformin and sulfonylurea users with type 2 diabetes mellitus (T2DM). Methods: This population-based retrospective cohort study included male patients with T2DM presenting to public hospitals/clinics in Hong Kong between January 1, 2000, and December 31, 2009. We only included patients prescribed either, but not both, metformin or sulfonylurea. All patients were followed up until December 31, 2019. The primary outcome was new-onset prostate cancer and the secondary outcome was all-cause mortality. One-to-one propensity score matching was performed between metformin and sulfonylurea users based on demographics, comorbidities, antidiabetic and cardiovascular medications, fasting blood glucose level, and hemoglobin A1c level. Subgroup analyses based on age and use of androgen deprivation therapy were performed. Results: The final study cohort consisted of 25,695 metformin users (mean [SD] age, 65.2 [11.8] years) and 25,695 matched sulfonylurea users (mean [SD] age, 65.3 [11.8] years) with a median follow-up duration of 119.6 months (interquartile range, 91.7–139.6 months) after 1:1 propensity score matching of 66,411 patients. Metformin users had lower risks of new-onset prostate cancer (hazard ratio, 0.80; 95% CI, 0.69–0.93; P=.0031) and all-cause mortality (hazard ratio, 0.89; 95% CI, 0.86–0.92; P<.0001) than sulfonylurea users. Metformin use was more protective against prostate cancer but less protective against all-cause mortality in patients aged <65 years (P for trend <.0001 for both) compared with patients aged ≥65 years. Metformin users had lower risk of all-cause mortality than sulfonylurea users, regardless of the use of androgen deprivation therapy (P for trend <.0001) among patients who developed prostate cancer. Conclusions: Metformin use was associated with significantly lower risks of new-onset prostate cancer and all-cause mortality than sulfonylurea use in male patients with T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study

Lee¹,

Zhou

Hui

et al. 2022

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

show abstract

“…Weight loss could increase testosterone levels, indicating that testosterone deficiency is functional (45). Weight loss bariatric surgery-induced resulted in a significant increase in Testosterone levels (46). In contrast, lower testosterone level after androgen deprivation therapy is associated with weight gain (45).…”

Section: Discussionmentioning

confidence: 99%

Testosterone deficiency in non-obese type 2 diabetic male patients

Gouda

Aboelnaga

Elbeltagy

et al. 2022

Arch Ital Urol Androl

Self Cite

View full text Add to dashboard Cite

Background and aims: it is unclear whether male hypogonadism is ascribable to the diabetic state per se, or because of other factors, such as obesity or age. We aimed to investigate the prevalence and identify the predictors for testosterone deficiency among non-obese type 2 diabetic males. Methods: This cross-sectional study was conducted on 95 nonobese type 2 diabetic males with BMI below 30. We evaluated the total testosterone (TT) levels to determine prevalence and risk factors of testosterone deficiency. Serum TT ≤ 300 ng/dl defined testosterone deficiency. Results: The prevalence of testosterone deficiency was 29.1%. Testosterone deficient patients had statistically significantly higher visceral adiposity index (VAI), waist, and triglyceride in comparison with normal testosterone patients. TT level correlated with VAI, waist, BMI, LH, and age. VAI was the only significant predictor of TT levels even after adjustment for age and BMI in regression analysis. Furthermore, VAI was a statistically significant risk factor for testosterone deficiency in binary logistic analysis. Conclusions: testosterone deficient non-obese type 2 diabetic male patients had elevated VAI, waist, and triglyceride. Moreover, elevated VAI was a risk factor for testosterone deficiency. VAI could be an easily applicable and reliable index for the evaluation and prediction in type 2 non-obese diabetic males.

show abstract

“…In diabetic patients with PCa, metformin may reduce the metabolic side effects incurred by ADT as well as promote its efficacy 5 . Therefore, metformin used in conjunction with ADT may lower the rate of hospitalization and its related costs.…”

Section: Metformin Non‐users (N = 687) Metformin Users (N = 1284) Unw...mentioning

confidence: 99%

“…4 In diabetic patients with PCa, metformin may reduce the metabolic side effects incurred by ADT as well as promote its efficacy. 5 Therefore, metformin used in conjunction with ADT may lower the rate of hospitalization and its related costs. This may help alleviate the economic burden of PCa, which is an increasingly important concern in Asia where its incidence is rising.…”

mentioning

confidence: 99%

Metformin use and hospital attendance‐related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based cohort study

Lee

Hui²,

Chung³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes

Cited by 6 publications

References 26 publications

Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study

Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study

Testosterone deficiency in non-obese type 2 diabetic male patients

Metformin use and hospital attendance‐related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population‐based cohort study

Contact Info

Product

Resources

About